Core Laboratories (CLB) AI Stock Analysis

• Market Cap: $493.79M
• Dividend Yield: 0.38%
• Average Volume (3M): 539.17K
• Price to Earnings (P/E): 16.6
• Beta (1Y): 0.91
• Revenue Growth: 0.70%
• EPS Growth: 5.97%
• Country: US
• Employees: 3,400
• Sector: Energy
• Sector Strength: 61
• Industry: Oil & Gas Equipment & Services
• EPS (TTM): 0.19
• Shares Outstanding: 46,893,840
• 10 Day Avg. Volume: 563,727
• 30 Day Avg. Volume: 539,171
• PEG Ratio: 3.80
• Price to Book (P/B): 2.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.74
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 0.18
• Enterprise Value/Gross Profit: 1.94
• Enterprise Value/Ebitda: 0.74
• 1Y Price Target: $12.50
• Price Target Upside: 18.71% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 61 Neutral
• Price Target: $11.00 ▲(4.46%Upside)

Core Laboratories shows strong financial performance and positive corporate events, but faces technical challenges and valuation concerns. The earnings call highlighted both strengths and ongoing market risks, leading to a moderate overall stock score.

Positive Factors

Geopolitical Factors

Potential easing of geopolitical tensions between Russia and Ukraine could serve as a positive catalyst for the company.

Stock Upgrade

The stock has been upgraded to Neutral, reflecting a more balanced risk/reward scenario.

Target Price Increase

The target price for the stock has been raised to $16, indicating improved cash dynamics over time.

Negative Factors

Operational Challenges

Production Enhancement has shrunk to just 11% of total company operating income, indicating challenges in that segment.

Core Laboratories Business Overview & Revenue Model

Company Description

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.

How the Company Makes Money

Core Laboratories generates revenue primarily through its two main business segments: Reservoir Description and Production Enhancement. The Reservoir Description segment provides laboratory-based analytical and field services to characterize and evaluate the properties of oil and gas reservoirs. This includes services such as core and fluid analysis, which are critical for understanding reservoir conditions and maximizing resource extraction. The Production Enhancement segment focuses on providing technologies and services that improve the efficiency and output of oil and gas wells. This includes services like hydraulic fracturing diagnostics and well perforation. Core Laboratories also benefits from long-term contracts and strategic partnerships with major oil companies, which ensure a steady revenue stream. The company's emphasis on proprietary technologies and innovation is a significant factor in maintaining its competitive edge and driving its earnings.

Core Laboratories Financial Statement Overview

Summary

Core Laboratories demonstrates financial resilience with a strong income statement and stable cash flow generation. The company is effectively managing its operational costs and generating consistent revenue growth. The balance sheet shows a balanced approach to leverage, although there is room for improvement in equity stability.

Income Statement

Core Laboratories shows a consistent improvement in its revenue and profitability. The gross profit margin and net profit margin are improving, indicating operational efficiency. Revenue growth has been steady with a positive trend over the years. The EBIT and EBITDA margins are healthy, reflecting the company's ability to manage its operational costs effectively.

Balance Sheet

The company's balance sheet is stable, with a favorable debt-to-equity ratio showing manageable leverage. The equity ratio indicates a solid financial foundation, but there has been fluctuation in stockholders' equity. The return on equity is positive and improving, highlighting effective use of equity to generate profits.

Cash Flow

The cash flow statement reflects good cash generation capacity, with consistent free cash flow and operating cash flow relative to net income. There is a positive trend in free cash flow growth, which supports future investments and debt management. The operating cash flow to net income ratio is strong, demonstrating efficient cash operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	523.85M	509.79M	489.74M	470.25M	487.27M
Gross Profit	88.37M	94.05M	78.92M	83.84M	91.63M
EBITDA	73.27M	70.42M	58.69M	63.78M	-56.73M
Net Income	31.40M	36.67M	19.45M	19.73M	-97.21M
Balance Sheet
Total Assets	590.41M	586.39M	578.35M	580.85M	568.58M
Cash, Cash Equivalents and Short-Term Investments	19.16M	15.12M	15.43M	17.70M	13.81M
Total Debt	180.14M	215.38M	222.39M	250.26M	326.98M
Total Liabilities	332.67M	356.59M	389.40M	419.85M	493.01M
Stockholders Equity	251.99M	224.81M	184.26M	156.45M	71.51M
Cash Flow
Free Cash Flow	43.36M	14.21M	14.74M	23.04M	45.99M
Operating Cash Flow	56.39M	24.79M	24.96M	36.58M	57.87M
Investing Cash Flow	-6.39M	-6.65M	-3.86M	-10.22M	7.85M
Financing Cash Flow	-45.96M	-18.45M	-23.38M	-22.46M	-63.01M

Core Laboratories Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLB, the sentiment is Negative. The current price of 10.53 is below the 20-day moving average (MA) of 11.95, below the 50-day MA of 11.76, and below the 200-day MA of 15.37, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 38.82 is Neutral, neither overbought nor oversold. The STOCH value of 4.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLB.

Core Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TTI	81 Outperform	$546.45M	4.74	54.03%	―	-3.23%	1031.00%
NESR	74 Outperform	$643.34M	8.34	1.53%	―	―	―
MRC	71 Outperform	$1.18B	41.18	8.29%	―	-9.84%	-111.71%
CLB	61 Neutral	$493.79M	16.63	11.82%	0.38%	0.70%	5.97%
OIS	54 Neutral	$295.69M	43.46	0.95%	―	-12.15%	―
PUMP	49 Neutral	$556.96M	―	-16.86%	―	-10.91%	-580.59%
Sector *	44 Neutral	AU$1.46B	-8.31	-20.28%	7.49%	0.96%	-28.36%

Core Laboratories Corporate Events

Core Laboratories Reports Strong Q2 Results and Dividend

On July 22, 2025, Core Laboratories Inc. entered into a Ninth Amended and Restated Credit Agreement, increasing its borrowing commitment to $150 million and extending the maturity date to July 22, 2029. This move aligns with the company’s strategic focus on expanding its global business and enhancing its financial flexibility. On July 23, 2025, Core Laboratories announced a quarterly cash dividend and reported second-quarter 2025 results, highlighting a 5% sequential revenue increase to $130.2 million and a 23% rise in operating income. The company also opened a new laboratory in Saudi Arabia and completed significant projects in Brazil and the North Sea, reinforcing its market position and commitment to delivering value to clients and shareholders.

The most recent analyst rating on (CLB) stock is a Sell with a $13.00 price target. To see the full list of analyst forecasts on Core Laboratories stock, see the CLB Stock Forecast page.

Core Laboratories Shareholders Approve Key Governance Items

On May 21, 2025, Core Laboratories Inc. held its Annual Meeting of Shareholders in Houston, Texas, where all proposed items were approved. Shareholders elected one new and re-elected two Class II Directors, ratified KPMG as the independent public accountant for 2025, and approved the executive compensation policies, reflecting strong shareholder support for the company’s governance and financial strategies.

The most recent analyst rating on (CLB) stock is a Sell with a $13.00 price target. To see the full list of analyst forecasts on Core Laboratories stock, see the CLB Stock Forecast page.